{"id":"intravesical-solution","_fda":{"id":"f2385edd-45ba-4ce8-97a0-ac301d067536","set_id":"8739ae02-e4c5-0fa2-e053-2a91aa0a1b74","openfda":{"unii":["2C6NUM6878"],"route":["INTRAVESICAL"],"rxcui":["313567"],"spl_id":["f2385edd-45ba-4ce8-97a0-ac301d067536"],"brand_name":["Valrubicin Intravesical Solution"],"spl_set_id":["8739ae02-e4c5-0fa2-e053-2a91aa0a1b74"],"package_ndc":["24201-101-04"],"product_ndc":["24201-101"],"generic_name":["VALRUBICIN INTRAVESICAL SOLUTION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["VALRUBICIN"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA206430"],"is_original_packager":[true]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant females [see Clinical Pharmacology ( 12.1 and 12.3 )] . There are no available data in pregnant females to inform the drug-associated risk. In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions [see Data] . Advise females who are or might become pregnant of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daily intravenous administration of valrubicin to pregnant rats during the period of organogenesis at doses ≥ 12 mg/kg (about 0.2 times the recommended human intravesical dose on a mg/m 2 basis) was embryo-fetal toxic and teratogenic. Administration of 12 mg/kg resulted in fetal malformations. A dose of 24 mg/kg (about 0.3 times the recommended human intravesical dose on a mg/m 2 basis) caused numerous, severe alterations in the skull and skeleton of the developing fetuses. This dose also caused an increase in fetal resorptions and a decrease in viable fetuses."],"overdosage":["10 OVERDOSAGE There is no known antidote for overdoses of valrubicin intravesical solution. The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin intravesical solution is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder rupture/perforation). Under such inadvertent exposures in the peritoneal cavity, the expected toxicities include leukopenia and neutropenia, beginning within 1 week of dose administration, with nadirs by the second week, and recovery generally by the third week. If valrubicin intravesical solution is administered when bladder rupture or perforation is suspected, weekly monitoring of complete blood counts should be performed for 3 weeks."],"references":["15 REFERENCES 1. OSHA Hazardous Drugs. OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html."],"description":["11 DESCRIPTION Valrubicin Intravesical Solution, USP contains valrubicin (N-trifluoroacetyladriamycin-14-valerate), which is a semisynthetic analog of the anthracycline doxorubicin as a cytotoxic agent. The chemical name of valrubicin is (2 S - cis )-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L- lyxo -hexopyranosyl]oxyl]-2-naphthacenyl]-2-oxoethylpentanoate. Valrubicin is an orange or orange-red powder that is highly lipophilic, soluble in methylene chloride, ethanol, methanol and acetone, and relatively insoluble in water. Its chemical formula is C 34 H 36 F 3 NO 13 and its molecular weight is 723.65. The chemical structure is shown in FIGURE 1. FIGURE 1. Chemical Structure of Valrubicin Valrubicin Intravesical Solution, USP is intended for intravesical administration in the urinary bladder. It is supplied as a nonaqueous solution that should be diluted before intravesical administration. Each vial of Valrubicin Intravesical Solution, USP contains 200 mg valrubicin at a concentration of 40 mg/mL in 5 mL of 50% polyoxyl castor oil/50% v/v dehydrated alcohol, USP without preservatives or other additives. The solution is sterile and nonpyrogenic. structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Valrubicin Intravesical Solution, USP is a sterile, clear red solution in polyoxyl castor oil/dehydrated alcohol, USP, containing 40 mg valrubicin per mL. Valrubicin Intravesical Solution, USP is available in single-use, clear glass vials, individually packaged in the following sizes: NDC 24201-101-04 Carton of four 200 mg/5 mL single-use vials Store vials under refrigeration at 2°-8°C (36°-46°F) in the carton. DO NOT FREEZE. The container closure is not made with natural rubber latex."],"geriatric_use":["8.5 Geriatric Use Because carcinoma in situ of the bladder generally occurs in older individuals, 85% of the patients enrolled in the clinical studies of valrubicin intravesical solution were more than 60 years of age (49% of the patients were more than 70 years of age). In the primary efficacy studies, the mean age of the population was 69.5 years. There are no specific precautions regarding use of valrubicin intravesical solution in geriatric patients who are otherwise in good health."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20220630","clinical_studies":["14 CLINICAL STUDIES Valrubicin intravesical solution was administered intravesically to a total of 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses ranging from 200 to 900 mg. One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks. Patients receiving valrubicin intravesical solution for refractory carcinoma in situ were monitored for disease recurrence or progression with cystoscopy, biopsy, and urine cytology every 3 months. In the 90 study patients with BCG-refractory carcinoma in situ (CIS), 70% had received at least 2 courses of BCG and 30% had received one course of BCG and at least one additional course of treatment with another agent(s) - e.g., mitomycin, thiotepa, or interferon. Valrubicin intravesical solution was administered beginning at least two weeks after transurethral resection and/or fulguration. After intravesical administration of valrubicin intravesical solution, 16 patients (18%) had a complete response documented by bladder biopsies and cytology at 6 months following initiation of therapy. Median duration of response from start of treatment varied according to the method of analysis (13.5 months if measured to last bladder biopsy without tumor and 21 months if measured until time of documented recurrence). A retrospective analysis in the 16 patients with complete response to valrubicin intravesical solution demonstrated that time to recurrence of their disease after treatment with valrubicin intravesical solution was longer than time to recurrence after previous courses of intravesical therapy. Of the 90 patients with BCG-refractory CIS, 11% (10 patients) developed metastatic or deeply-invasive bladder cancer during follow-up; four of these patients, none who underwent cystectomy, died with metastatic bladder cancer and six were found to have developed stage progression to deeply-invasive disease (T3), with lymph node involvement in one patient, at the time of cystectomy. It is uncertain to what extent the development of advanced bladder cancer in these patients was due to the delay in cystectomy required to receive treatment with valrubicin intravesical solution (3 months was the time of follow-up to determine response), as cystectomy was often delayed or was never performed despite failure of treatment with valrubicin intravesical solution. In the 10 patients documented to have invasive bladder cancer or metastatic disease, the delay between the time of treatment failure (when cystectomy should have been performed) and cystectomy or documentation of advanced bladder cancer was a median of 17.5 months."],"pharmacokinetics":["12.3 Pharmacokinetics When 800 mg valrubicin intravesical solution was administered intravesically to patients with carcinoma in situ , valrubicin intravesical solution penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytotoxicity to human bladder cells cultured in vitro . During the two-hour dose-retention period, the metabolism of valrubicin intravesical solution to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol in bladder tissue was negligible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of valrubicin intravesical solution, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of valrubicin intravesical solution were absorbed into the plasma. N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol were measured in blood. Total systemic exposure to anthracyclines during and after intravesical administration of valrubicin intravesical solution is dependent upon the condition of the bladder wall. The mean AUC 0-6 hours (total anthracyclines exposure) for an intravesical dose of 900 mg of valrubicin intravesical solution administered 2 weeks after transurethral resection of bladder tumors (n=6) was 78 nmol/L•hr. In patients receiving 800 mg of valrubicin intravesical solution 5 to 51 minutes after typical (n=8) and extensive (n=5) TURB tumors, the mean AUC 0-6 hours values for total anthracyclines were 409 and 788 nmol/L•hr, respectively. The AUC 0-6 hours total exposure to anthracyclines was 18,382 nmol/L•hr in one patient who experienced a perforated bladder following a transurethral resection that occurred 5 minutes before administration of an intravesical dose of 800 mg of valrubicin intravesical solution. Administration of a comparable intravenous dose of valrubicin intravesical solution (600 mg/m 2 ; n=2) as a 24-hour infusion resulted in an AUC 0-6 hours for total anthracyclines of 11,975 nmol/L•hr. These results are shown in FIGURE 2. FIGURE 2. Comparison of Mean AUC 0-6 hours in Valrubicin Intravesical Solution Clinical Studies (N=number of patients) figure-2"],"adverse_reactions":["6 ADVERSE REACTIONS The most frequently reported adverse reactions ( > 5%) after administration of valrubicin intravesical solution are urinary frequency, dysuria, urinary urgency, bladder spasm, hematuria, bladder pain, urinary incontinence, cystitis, urinary tract infection, nocturia, local burning symptoms, abdominal pain, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Hikma at us.hikma@primevigilance.com or call 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of valrubicin intravesical solution was assessed in 230 patients with transitional cell carcinoma of the bladder, including 205 patients who received multiple weekly doses. One hundred seventy-nine of the 205 patients received the approved dose and schedule of 800 mg weekly for multiple weeks. Approximately 84% of patients who received intravesical valrubicin intravesical solution in clinical studies experienced local adverse reactions. The local adverse reactions associated with valrubicin intravesical solution usually occur during or shortly after instillation and resolve within 1 to 7 days after the instillate is removed from the bladder. Seven out of 143 patients (5%) who were scheduled to receive six doses of valrubicin intravesical solution failed to receive all of the planned doses because of the occurrence of local bladder symptoms. TABLE 1 displays the frequency of the local adverse reactions at baseline and during treatment among 179 patients who received 800 mg doses of valrubicin intravesical solution in a multiple-cycle treatment regimen. TABLE 1 Local Adverse Reactions Before and During Treatment with Valrubicin Intravesical Solution (N=179) Adverse Reaction Before Treatment During 6-week Course of Treatment ANY LOCAL BLADDER SYMPTOM 45% 88% Urinary Frequency 30% 61% Dysuria 11% 56% Urinary Urgency 27% 57% Bladder Spasm 3% 31% Hematuria 11% 29% Bladder Pain 6% 28% Urinary Incontinence 7% 22% Cystitis 4% 15% Nocturia 2% 7% Local Burning Symptoms – Procedure Related 0% 5% Urethral Pain 0% 3% Pelvic Pain 1% 1% Hematuria (Gross) 0% 1% TABLE 2 displays the adverse reactions other than local bladder symptoms that occurred in 1% or more of the 230 patients who received at least one dose of valrubicin intravesical solution in a clinical trial. TABLE 2 Systemic Adverse Reactions (≥ 1%) Following Intravesical Administration of Valrubicin Intravesical Solution (N=230) Body System Preferred Term Body as a Whole Abdominal Pain 5% Asthenia 4% Headache 4% Malaise 4% Back Pain 3% Chest Pain 3% Fever 2% Cardiovascular Vasodilation 2% Digestive Nausea 5% Diarrhea 3% Vomiting 2% Flatulence 1% Hemic and Lymphatic Anemia 2% Metabolic and Nutritional Hyperglycemia 1% Peripheral Edema 1% Musculoskeletal Myalgia 1% Nervous Dizziness 3% Respiratory Pneumonia 1% Skin and Appendages Rash 3% Urogenital Urinary Tract Infection 15% Urinary Retention 4% Hematuria (miscroscopic) 3% Adverse reactions other than local reactions that occurred in less than 1% of the patients who received valrubicin intravesical solution intravesically in clinical trials are listed below. Digestive System: Tenesmus Metabolic and Nutritional: Nonprotein nitrogen increased Skin and Appendages: Pruritus Special Senses: Taste loss Urogenital System: Local skin irritation, poor urine flow, and urethritis"],"contraindications":["4 CONTRAINDICATIONS Valrubicin intravesical solution is contraindicated in patients with: • Perforated bladder [see Warnings and Precautions ( 5.2 )] • Known hypersensitivity to anthracyclines or polyoxyl castor oil • Active urinary tract infection • Small bladder capacity and unable to tolerate a 75 mL instillation • Perforated bladder or compromised bladder mucosa ( 4 , 5.2 ) • Hypersensitivity to anthracyclines or polyoxyl castor oil. ( 4 ) • Concurrent urinary tract infections. ( 4 ) • Patients with a small bladder capacity unable to tolerate a 75 mL instillation. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No drug interaction studies were conducted."],"mechanism_of_action":["12.1 Mechanism of Action Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G 2 . Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic acid metabolism. In cells, it inhibits the incorporation of nucleosides into nucleic acids, causes chromosomal damage, and arrests the cell cycle in G 2 . Although valrubicin does not bind strongly to DNA, valrubicin metabolites interfere with the normal DNA breaking-resealing action of DNA topoisomerase II. 12.3 Pharmacokinetics When 800 mg valrubicin intravesical solution was administered intravesically to patients with carcinoma in situ , valrubicin intravesical solution penetrated into the bladder wall. The mean total anthracycline concentration measured in bladder tissue exceeded the levels causing 90% cytotoxicity to human bladder cells cultured in vitro . During the two-hour dose-retention period, the metabolism of valrubicin intravesical solution to its major metabolites N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol in bladder tissue was negligible. After retention, the drug was almost completely excreted by voiding the instillate. Mean percent recovery of valrubicin intravesical solution, N-trifluoroacetyladriamycin, and total anthracyclines in 14 urine samples from six patients was 98.6%, 0.4%, and 99.0% of the total administered drug, respectively. During the two-hour dose-retention period, only nanogram quantities of valrubicin intravesical solution were absorbed into the plasma. N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol were measured in blood. Total systemic exposure to anthracyclines during and after intravesical administration of valrubicin intravesical solution is dependent upon the condition of the bladder wall. The mean AUC 0-6 hours (total anthracyclines exposure) for an intravesical dose of 900 mg of valrubicin intravesical solution administered 2 weeks after transurethral resection of bladder tumors (n=6) was 78 nmol/L•hr. In patients receiving 800 mg of valrubicin intravesical solution 5 to 51 minutes after typical (n=8) and extensive (n=5) TURB tumors, the mean AUC 0-6 hours values for total anthracyclines were 409 and 788 nmol/L•hr, respectively. The AUC 0-6 hours total exposure to anthracyclines was 18,382 nmol/L•hr in one patient who experienced a perforated bladder following a transurethral resection that occurred 5 minutes before administration of an intravesical dose of 800 mg of valrubicin intravesical solution. Administration of a comparable intravenous dose of valrubicin intravesical solution (600 mg/m 2 ; n=2) as a 24-hour infusion resulted in an AUC 0-6 hours for total anthracyclines of 11,975 nmol/L•hr. These results are shown in FIGURE 2. FIGURE 2. Comparison of Mean AUC 0-6 hours in Valrubicin Intravesical Solution Clinical Studies (N=number of patients) figure-2"],"indications_and_usage":["1 INDICATIONS AND USAGE Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. • Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Delaying cystectomy can lead to development of metastatic bladder cancer, which is lethal. ( 5.1 ) • Do not administer valrubicin intravesical solution to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised. ( 5.2 , 12.3 ) • Evaluate the status of the bladder before the intravesical instillation of valrubicin intravesical solution. ( 5.3 ) • Use with caution in patients with severe irritable bladder symptoms. ( 5.4 ) • Embryo-Fetal Toxicity: Valrubicin intravesical solution can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.5 , 8.1 , 8.3 ) 5.1 Risk of Metastatic Bladder Cancer with Delayed Cystectomy Inform patients that valrubicin intravesical solution has been shown to induce complete response in only about 1 in 5 patients with BCG-refractory CIS, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal. The exact risk of developing metastatic bladder cancer from such a delay may be difficult to assess [see Clinical Studies ( 14 )] but increases the longer cystectomy is delayed in the presence of persisting CIS. If there is not a complete response of CIS to treatment after 3 months or if CIS recurs, reconsider cystectomy. 5.2 Risk in Patients with Perforated Bladder Evaluate the bladder before the intravesical instillation of drug and do not administer valrubicin intravesical solution to patients with a perforated bladder or to those in whom the integrity of the bladder mucosa has been compromised [see Contraindications ( 4 )] . In case of bladder perforation, delay the administration of valrubicin intravesical solution until bladder integrity has been restored. One patient with a perforated bladder who received 800 mg of valrubicin intravesical solution intravesically developed severe leukopenia and neutropenia approximately two weeks after drug administration [see Clinical Pharmacology ( 12.3 )] . 5.3 Risk in Patients Undergoing Transurethral Resection of the Bladder (TURB) To avoid systemic exposure to valrubicin intravesical solution for the patients undergoing TURB, evaluate the status of the bladder before the intravesical instillation of drug. Delay administration at least two weeks after transurethral resection and/or fulguration. 5.4 Risk in Patients with Irritable Bladder Symptoms Use valrubicin intravesical solution with caution in patients with severe irritable bladder symptoms. Bladder spasm and spontaneous discharge of the intravesical instillate may occur; clamping of the urinary catheter is not advised. 5.5 Embryo-Fetal Toxicity Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 and 12.3 )] . In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions. Advise females who might become pregnant of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months following the final dose [see Use in Specific Populations ( 8.1 and 8.3 )] ."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of valrubicin has not been evaluated. In vitro, valrubicin was mutagenic in the bacterial reverse mutation (Ames) assay and clastogenic in the chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells. Studies in animals evaluating the effects of valrubicin on male or female fertility have not been conducted. Based on effects on male reproductive organs in general toxicology studies in dogs with intravesical instillation, valrubicin may impair fertility in male patients. When instilled into the bladder of male dogs weekly for 6 weeks, valrubicin caused mild to moderate atrophy of the prostate with inflammation, diffuse decrease in acinar size, epithelial changes. It also caused testicular degeneration, marked germ cell depletion, spermatid giant cells and karyomegaly."],"adverse_reactions_table":["
TABLE 1 Local Adverse Reactions Before and During Treatment with Valrubicin Intravesical Solution (N=179)
Adverse ReactionBefore TreatmentDuring 6-weekCourse of Treatment
ANY LOCALBLADDER SYMPTOM45%88%
Urinary Frequency30%61%
Dysuria11%56%
Urinary Urgency27%57%
Bladder Spasm3%31%
Hematuria11%29%
Bladder Pain6%28%
Urinary Incontinence7%22%
Cystitis4%15%
Nocturia2%7%
Local Burning Symptoms –Procedure Related0%5%
Urethral Pain0%3%
Pelvic Pain1%1%
Hematuria (Gross)0%1%
","
TABLE 2 Systemic Adverse Reactions (≥ 1%) Following Intravesical Administration of Valrubicin Intravesical Solution (N=230)
Body System Preferred Term
Body as a Whole
Abdominal Pain5%
Asthenia4%
Headache4%
Malaise4%
Back Pain3%
Chest Pain3%
Fever2%
Cardiovascular
Vasodilation2%
Digestive
Nausea5%
Diarrhea3%
Vomiting2%
Flatulence1%
Hemic and Lymphatic
Anemia2%
Metabolic and Nutritional
Hyperglycemia1%
Peripheral Edema1%
Musculoskeletal
Myalgia1%
Nervous
Dizziness3%
Respiratory
Pneumonia1%
Skin and Appendages
Rash3%
Urogenital
Urinary Tract Infection15%
Urinary Retention4%
Hematuria (miscroscopic)3%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Risk of Metastatic Bladder Cancer with Delayed Cystectomy • Inform patients that valrubicin intravesical solution has been shown to induce complete responses in only about 1 in 5 patients, and that delaying cystectomy could lead to development of metastatic bladder cancer, which is lethal. Discuss the relative risk of cystectomy versus the risk of metastatic bladder cancer [see Clinical Trials ( 14 )] and that the risk increases the longer cystectomy is delayed in the presence of persisting CIS. Local Adverse Reactions Before and During Treatment • Inform patients that the major acute toxicities from valrubicin intravesical solution are related to irritable bladder symptoms that may occur during instillation and retention of valrubicin intravesical solution and for a limited period following voiding [see Adverse Reactions ( 6.1 )] . • Inform patients that for the first 24 hours following administration, red-tinged urine is typical. • Advise patients to report prolonged irritable bladder symptoms or prolonged passage of red-colored urine immediately to their physician. • Instruct patients to maintain adequate hydration following valrubicin intravesical solution treatment. Embryo-Fetal Toxicity • Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment with valrubicin intravesical solution and for 6 months after the last dose. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.5 ), Use in Specific Populations ( 8.1 and 8.3 )] . • Advise male patients with female partners of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 3 months after the last dose [see Use in Specific Populations ( 8.3 )] . Lactation • Advise females not to breastfeed during treatment with valrubicin intravesical solution and for 2 weeks after the last dose [see Use in Specific Populations ( 8.2 )] . Healthcare professionals can email Hikma at us.hikma@primevigilance.com or call 1-877-845-0689 for information on this product. Manufactured by: The University of Iowa Pharmaceuticals Iowa City, Iowa 52242 Manufactured for: Hikma Berkeley Heights, NJ 07922 Rev. June 2022"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • For Intravesical Use Only. ( 2.1 ) • Valrubicin intravesical solution is recommended at a dose of 800 mg administered intravesically once a week for six weeks. ( 2.1 ) • Delay administration at least two weeks after transurethral resection and/or fulguration. ( 2.1 ) • Warm valrubicin intravesical solution slowly to room temperature, but do not heat. ( 2.1 ) • Use caution when handling and preparing the solution of valrubicin intravesical solution. ( 2.2 ) 2.1 Recommended Dosing For Intravesical Use Only. Do NOT administer by intravenous or intramuscular routes. Valrubicin intravesical solution is recommended at a dose of 800 mg administered intravesically once a week for six weeks. Delay administration at least two weeks after transurethral resection and/or fulguration [see Warnings and Precautions ( 5.2 , 5.3 )]. 2.2 Preparation, Handling, and Administration Handle and dispose of valrubicin intravesical solution in a manner consistent with other cytotoxic drugs. 1 The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug. Valrubicin intravesical solution contains polyoxyl castor oil, which has been known to cause leaching of di(2-ethylhexyl) phthalate (DEHP) a hepatotoxic plasticizer, from polyvinyl chloride (PVC) bags and intravenous tubing. Valrubicin intravesical solution should be prepared and stored in glass, polypropylene, or polyolefin containers and tubing. It is recommended that non-DEHP containing administration sets, such as those that are polyethylene-lined, be used. Valrubicin intravesical solution is a clear red solution. Visually inspect for particulate matter and discoloration prior to administration. At temperatures below 4°C (39°F), polyoxyl castor oil may begin to form a waxy precipitate. If this happens, the vial should be warmed in the hand until the solution is clear. If particulate matter is still seen, do not administer valrubicin intravesical solution. For each instillation, slowly allow four 5 mL vials (200 mg valrubicin/5 mL vial) to warm to room temperature, but do not heat. Withdraw 20 mL of valrubicin intravesical solution from the four vials and dilute with 55 mL of 0.9% Sodium Chloride Injection, USP to provide 75 mL of a diluted valrubicin intravesical solution. Valrubicin intravesical solution diluted in 0.9% Sodium Chloride Injection, USP for administration is stable for 12 hours at temperatures up to 25°C (77°F). Since compatibility data are not available, do not mix valrubicin intravesical solution with other drugs. Insert a urethral catheter into the patient's bladder under aseptic conditions, drain the bladder, and instill the diluted 75 mL valrubicin intravesical solution slowly via gravity flow over a period of several minutes. Withdraw the catheter and retain valrubicin intravesical solution in the bladder for two hours before voiding. At the end of two hours, all patients should void. Some patients may be unable to retain the drug for the full two hours. Instruct patients to maintain adequate hydration following valrubicin intravesical solution treatment [see Patient Counseling Information ( 17 )] ."],"spl_product_data_elements":["Valrubicin Intravesical Solution Valrubicin Intravesical Solution ALCOHOL POLYOXYL 35 CASTOR OIL NITROGEN VALRUBICIN VALRUBICIN"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 200 mg/5 mL sterile, clear red, solution in single-use vials for intravesical instillation upon dilution. • Injection: 200 mg/5 mL in single-use vials ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings in animal studies and its mechanism of action, valrubicin intravesical solution can cause fetal harm when administered to a pregnant females [see Clinical Pharmacology ( 12.1 and 12.3 )] . There are no available data in pregnant females to inform the drug-associated risk. In animal reproduction studies, intravenous administration of valrubicin to pregnant rats during the period of organogenesis at a dose about 0.2 times the recommended human intravesical dose caused embryo-fetal malformations and increased resorptions [see Data] . Advise females who are or might become pregnant of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically-recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Daily intravenous administration of valrubicin to pregnant rats during the period of organogenesis at doses ≥ 12 mg/kg (about 0.2 times the recommended human intravesical dose on a mg/m 2 basis) was embryo-fetal toxic and teratogenic. Administration of 12 mg/kg resulted in fetal malformations. A dose of 24 mg/kg (about 0.3 times the recommended human intravesical dose on a mg/m 2 basis) caused numerous, severe alterations in the skull and skeleton of the developing fetuses. This dose also caused an increase in fetal resorptions and a decrease in viable fetuses. 8.2 Lactation Risk Summary There are no data on the presence of valrubicin or its metabolites in human milk, the effects of valrubicin on the breast-fed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breast-fed infants from valrubicin, advise a lactating female not to breastfeed during treatment with valrubicin intravesical solution and for 2 weeks after the final dose. 8.3 Females and Males of Reproductive Potential Contraception Females Valrubicin intravesical solution can cause fetal harm when administered to a pregnant female. Advise females of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 6 months after the final dose [see Use in Specific Populations ( 8.1 )] . Males Based on genotoxicity findings, advise men with female partners of reproductive potential to use effective contraception during treatment with valrubicin intravesical solution and for 3 months following the final dose [see Non Clinical Toxicology ( 13.1 )] Infertility Males Studies of the effects of valrubicin intravesical solution on human male or female fertility have not been done. Based on findings in animal studies, valrubicin intravesical solution may impair fertility in males of reproductive potential [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Because carcinoma in situ of the bladder generally occurs in older individuals, 85% of the patients enrolled in the clinical studies of valrubicin intravesical solution were more than 60 years of age (49% of the patients were more than 70 years of age). In the primary efficacy studies, the mean age of the population was 69.5 years. There are no specific precautions regarding use of valrubicin intravesical solution in geriatric patients who are otherwise in good health."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL vial-label","Package/Label Display Panel carton-image"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of valrubicin has not been evaluated. In vitro, valrubicin was mutagenic in the bacterial reverse mutation (Ames) assay and clastogenic in the chromosomal aberration assay in Chinese Hamster Ovary (CHO) cells. Studies in animals evaluating the effects of valrubicin on male or female fertility have not been conducted. Based on effects on male reproductive organs in general toxicology studies in dogs with intravesical instillation, valrubicin may impair fertility in male patients. When instilled into the bladder of male dogs weekly for 6 weeks, valrubicin caused mild to moderate atrophy of the prostate with inflammation, diffuse decrease in acinar size, epithelial changes. It also caused testicular degeneration, marked germ cell depletion, spermatid giant cells and karyomegaly."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Urinary Frequency","drugRate":"61%","severity":"common","organSystem":""},{"effect":"Dysuria","drugRate":"56%","severity":"common","organSystem":""},{"effect":"Urinary Urgency","drugRate":"57%","severity":"common","organSystem":""},{"effect":"Bladder Spasm","drugRate":"31%","severity":"common","organSystem":""},{"effect":"Hematuria","drugRate":"29%","severity":"common","organSystem":""},{"effect":"Bladder Pain","drugRate":"28%","severity":"common","organSystem":""},{"effect":"Urinary Incontinence","drugRate":"22%","severity":"common","organSystem":""},{"effect":"Cystitis","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Urinary Tract Infection","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Nocturia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Local Burning Symptoms","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Abdominal Pain","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Urinary Retention","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Malaise","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Back Pain","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"3%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Pneumonia","drugRate":"1%","severity":"serious"},{"effect":"Anemia","drugRate":"2%","severity":"serious"},{"effect":"Fever","drugRate":"2%","severity":"serious"},{"effect":"Vomiting","drugRate":"2%","severity":"serious"},{"effect":"Vasodilation","drugRate":"2%","severity":"serious"},{"effect":"Chest Pain","drugRate":"3%","severity":"serious"},{"effect":"Rash","drugRate":"3%","severity":"serious"}]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Intravesical Solution","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:43:43.520003+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:44:14.988379+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:43:50.564180+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Intravesical Solution","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:43:51.360935+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:43:41.429317+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:44:07.553635+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:43:41.429378+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108251/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:43:51.882350+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA206430","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T06:43:41.429389+00:00"}},"_dailymed":{"setId":"8739ae02-e4c5-0fa2-e053-2a91aa0a1b74","title":"VALRUBICIN INTRAVESICAL SOLUTION SOLUTION, CONCENTRATE [HIKMA PHARMACEUTICALS USA INC.]"},"aiSummary":"Intravesical Solution, marketed by Ankara Training and Research Hospital, is positioned as a treatment for BCG-refractory CIS of the urinary bladder. The key strength lies in its specific indication for a challenging patient population, with a key composition patent expiring in 2028. The primary risk is the limited revenue data and lack of detailed clinical trial results, which may affect market adoption and competitive positioning.","_scrapedAt":"2026-03-28T01:16:54.156Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T06:44:14.988845+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"intravesical-solution-bcg-refractory-cis-of-the-urin","name":"BCG-refractory CIS of the urinary bladder","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality","diagnosticRequired":null,"brandNameForIndication":""}]},"trialDetails":[{"nctId":"NCT07495072","phase":"NA","title":"Early vs Delayed Intravesical Blad-Care During BCG Therapy","status":"RECRUITING","sponsor":"BLAD-HYA Group","startDate":"2025-11-03","conditions":"Urinary Bladder Neoplasms, BCG-Induced Cystitis","enrollment":56},{"nctId":"NCT02870738","phase":"PHASE2","title":"Bladder Directed vs. Pelvic Floor Therapy in IC/BPS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corewell Health East","startDate":"2017-04-21","conditions":"Cystitis, Interstitial, Painful Bladder Syndrome","enrollment":128},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT05055050","phase":"PHASE1","title":"A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-01-24","conditions":"Bladder Cancer, Bladder","enrollment":10},{"nctId":"NCT07474519","phase":"PHASE4","title":"Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Non-Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT07387315","phase":"PHASE4","title":"A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","status":"NOT_YET_RECRUITING","sponsor":"TriHealth Inc.","startDate":"2026-02","conditions":"Overactive Bladder, Neurogenic Bladder, Urge Incontinence","enrollment":96},{"nctId":"NCT07382271","phase":"NA","title":"Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02","conditions":"Urinary Tract Infections, Urinary Tract Infections Caused by Drug-resistant Bacteria","enrollment":6},{"nctId":"NCT06331299","phase":"PHASE3","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2024-08-29","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":99},{"nctId":"NCT05375903","phase":"PHASE1","title":"A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2022-06-01","conditions":"Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder","enrollment":51},{"nctId":"NCT04369560","phase":"EARLY_PHASE1","title":"Virtual Histology of the Bladder Wall for Bladder Cancer Staging","status":"RECRUITING","sponsor":"Jodi Maranchie","startDate":"2025-05-23","conditions":"Urinary Bladder Neoplasms","enrollment":42},{"nctId":"NCT07272603","phase":"EARLY_PHASE1","title":"Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-12-15","conditions":"Bladder (Urothelial, Transitional Cell) Cancer","enrollment":5},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":"Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder","enrollment":50},{"nctId":"NCT04386746","phase":"PHASE2","title":"Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-07-29","conditions":"Urothelial Carcinoma Bladder, Bladder Cancer","enrollment":27},{"nctId":"NCT06635889","phase":"PHASE2","title":"Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-26","conditions":"Nephrolithiasis","enrollment":116},{"nctId":"NCT07198451","phase":"PHASE2, PHASE3","title":"Efficacy of Gemcitabine Submucosal Injection for Preventing Recurrence in Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2025-10","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":320},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT07125924","phase":"NA","title":"Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-08-22","conditions":"Bladder Cancer, Radiation Cystitis","enrollment":54},{"nctId":"NCT04516434","phase":"NA","title":"Amplifying Sensation in Underactive Bladder","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-09-01","conditions":"Urinary Bladder, Underactive","enrollment":20},{"nctId":"NCT06013449","phase":"NA","title":"Efficacy of Pulsed Electromagnetic Field and Heparin/Bupivacaine Instillations","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-03","conditions":"Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome","enrollment":20},{"nctId":"NCT07027020","phase":"PHASE3","title":"Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09","conditions":"Spina Bifida","enrollment":60},{"nctId":"NCT05811377","phase":"EARLY_PHASE1","title":"Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay","status":"COMPLETED","sponsor":"Christopher J Chermansky, MD","startDate":"2023-03-29","conditions":"IC - Interstitial Cystitis","enrollment":8},{"nctId":"NCT06863220","phase":"NA","title":"Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Medipol University","startDate":"2025-06-01","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":60},{"nctId":"NCT05024734","phase":"PHASE2","title":"Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids","status":"RECRUITING","sponsor":"Roland Seiler-Blarer","startDate":"2023-02-21","conditions":"Bladder Cancer, Non-muscle Invasive","enrollment":34},{"nctId":"NCT06696794","phase":"PHASE3","title":"Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients","status":"RECRUITING","sponsor":"Shaogang Wang","startDate":"2025-02-17","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":180},{"nctId":"NCT04095572","phase":"PHASE4","title":"Alternative Prophylaxis in Female Recurrent Urinary Tract Infections","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-10-27","conditions":"Urinary Tract Infections, Urinary Tract Infection (UTI)","enrollment":50},{"nctId":"NCT06719232","phase":"","title":"Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation","status":"RECRUITING","sponsor":"Jahn Ferenc South Pest Teaching Hospital","startDate":"2024-10-01","conditions":"Interstitial Cystitis, Recurrent Cystitis, Haemorrhagic Cystitis","enrollment":300},{"nctId":"NCT05243550","phase":"PHASE3","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UroGen Pharma Ltd.","startDate":"2022-03-01","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":240},{"nctId":"NCT06632964","phase":"PHASE1","title":"A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-09-18","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":16},{"nctId":"NCT05600322","phase":"PHASE3","title":"Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer","status":"COMPLETED","sponsor":"Photocure","startDate":"2022-11-03","conditions":"Bladder Cancer","enrollment":158},{"nctId":"NCT05136898","phase":"PHASE3","title":"Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2021-11-30","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":8},{"nctId":"NCT04706598","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2021-06-09","conditions":"Urinary Bladder Neoplasms, Immunotherapy","enrollment":25},{"nctId":"NCT02808143","phase":"PHASE1","title":"Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-02-10","conditions":"Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03503513","phase":"PHASE2, PHASE3","title":"Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-08-24","conditions":"Urinary Tract Infections, Spinal Cord Injuries, Spinal Cord Diseases","enrollment":23},{"nctId":"NCT04688931","phase":"PHASE3","title":"A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"UroGen Pharma Ltd.","startDate":"2021-02-19","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":282},{"nctId":"NCT06427291","phase":"PHASE1","title":"Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-09-21","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT06374914","phase":"","title":"Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Dokuz Eylul University","startDate":"2024-04-09","conditions":"Bladder Cancer, BCG, Gemcitabine","enrollment":120},{"nctId":"NCT06227065","phase":"PHASE2","title":"Precise Neoadjuvant Chemoresection of Low Grade NMIBC","status":"NOT_YET_RECRUITING","sponsor":"University of Bern","startDate":"2024-10","conditions":"Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low-risk","enrollment":28},{"nctId":"NCT06209008","phase":"PHASE3","title":"Submucosal Intravesical Injection of Platelet-rich Plasma in the Treatment of Painful Bladder Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2021-04-01","conditions":"Painful Bladder Syndrome (PBS), Interstitial Cystitis","enrollment":30},{"nctId":"NCT04496219","phase":"PHASE2","title":"Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-01-22","conditions":"Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":45},{"nctId":"NCT06069453","phase":"NA","title":"Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.","status":"TERMINATED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2020-08-19","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":54},{"nctId":"NCT05975151","phase":"PHASE2","title":"Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-10-01","conditions":"Bladder Cancer","enrollment":63},{"nctId":"NCT05810623","phase":"PHASE3","title":"Single-Dose Intravesical Chemotherapy After Diagnostic URS","status":"NOT_YET_RECRUITING","sponsor":"David D'Andrea","startDate":"2023-06-01","conditions":"Upper Urinary Tract Urothelial Carcinoma, Bladder Cancer","enrollment":394},{"nctId":"NCT05084586","phase":"NA","title":"Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation","status":"UNKNOWN","sponsor":"Ankara Training and Research Hospital","startDate":"2019-10-01","conditions":"Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer","enrollment":100},{"nctId":"NCT03854721","phase":"PHASE1","title":"A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"Vaxiion Therapeutics","startDate":"2019-05-10","conditions":"Urothelial Carcinoma of the Urinary Bladder","enrollment":6},{"nctId":"NCT05564897","phase":"PHASE2","title":"Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2022-08-26","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT05415865","phase":"PHASE3","title":"The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder","status":"UNKNOWN","sponsor":"Herlev and Gentofte Hospital","startDate":"2022-09-12","conditions":"Urge Incontinence, Overactive Bladder, Anesthesia, Local","enrollment":50},{"nctId":"NCT03558503","phase":"PHASE2","title":"A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"UroGen Pharma Ltd.","startDate":"2018-10-15","conditions":"Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT03062059","phase":"PHASE2","title":"The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2018-03-01","conditions":"Urothelial Carcinoma","enrollment":134},{"nctId":"NCT05275647","phase":"PHASE2","title":"Efficacy and Safety of Low Energy Shock Wave Plus BotulinumToxin A in Treating Patients With Interstitial Cystitis","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2021-05-18","conditions":"Interstitial Cystitis","enrollment":75},{"nctId":"NCT03945110","phase":"PHASE1, PHASE2","title":"Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury","status":"COMPLETED","sponsor":"The University of Western Australia","startDate":"2019-09-18","conditions":"Spinal Cord Injuries","enrollment":10},{"nctId":"NCT04109092","phase":"PHASE1","title":"A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102","status":"WITHDRAWN","sponsor":"Eisai Inc.","startDate":"2020-02-13","conditions":"Urinary Bladder Neoplasms","enrollment":""},{"nctId":"NCT04661826","phase":"PHASE2","title":"ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.","status":"COMPLETED","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2010-05-17","conditions":"Non-Invasive Papillary Carcinoma of Bladder","enrollment":60},{"nctId":"NCT03560479","phase":"PHASE1, PHASE2","title":"A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Hamlet Pharma AB","startDate":"2018-05-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":52},{"nctId":"NCT03167151","phase":"PHASE1, PHASE2","title":"Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)","status":"TERMINATED","sponsor":"University of Oxford","startDate":"2018-03-02","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":6},{"nctId":"NCT03755089","phase":"PHASE4","title":"Oral vs Intravesical Analgesia for Office Bladder Botox Injections","status":"UNKNOWN","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2018-11-01","conditions":"Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence","enrollment":110},{"nctId":"NCT00427648","phase":"PHASE3","title":"Local Anesthetic Treatments for Overactive Bladder","status":"TERMINATED","sponsor":"Frank Tu","startDate":"2006-03","conditions":"Overactive Bladder","enrollment":22},{"nctId":"NCT04268810","phase":"PHASE4","title":"Prospective Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of PBS/Interstitial Cystitis","status":"TERMINATED","sponsor":"National Multiple Sclerosis Center","startDate":"2010-03","conditions":"Painful Bladder Syndrome, Interstitial Cystitis","enrollment":36},{"nctId":"NCT03671993","phase":"NA","title":"Clinical Effect Observation for Electrical Pudendal Nerve Stimulation in Treating Urethral Pain Syndrome","status":"COMPLETED","sponsor":"Shanghai Institute of Acupuncture, Moxibustion and Meridian","startDate":"2018-10-05","conditions":"Pelvic Pain Syndrome","enrollment":50},{"nctId":"NCT04147182","phase":"PHASE1","title":"Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection","status":"UNKNOWN","sponsor":"Dan Leibovici","startDate":"2018-12-02","conditions":"TCC","enrollment":15},{"nctId":"NCT03633994","phase":"PHASE2","title":"Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy","status":"UNKNOWN","sponsor":"The Christ Hospital","startDate":"2018-08-20","conditions":"Lower Urinary Tract Symptoms, Postoperative Urinary Tract Infection","enrollment":104},{"nctId":"NCT03299387","phase":"PHASE4","title":"INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2017-06-28","conditions":"Urinary Tract Infections","enrollment":""},{"nctId":"NCT00956176","phase":"NA","title":"Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"","conditions":"Cystitis, Bladder Diseases","enrollment":""},{"nctId":"NCT02204917","phase":"PHASE1, PHASE2","title":"CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children","status":"COMPLETED","sponsor":"Kassa Darge","startDate":"2014-07","conditions":"Vesico-Ureteral Reflux","enrollment":31},{"nctId":"NCT01393223","phase":"PHASE2","title":"Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome","status":"COMPLETED","sponsor":"Lipella Pharmaceuticals, Inc.","startDate":"2015-07-21","conditions":"Interstitial Cystitis","enrollment":21},{"nctId":"NCT02560584","phase":"PHASE3","title":"A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting","status":"COMPLETED","sponsor":"Photocure","startDate":"2015-10-01","conditions":"Bladder Cancer","enrollment":304},{"nctId":"NCT02856022","phase":"NA","title":"A Comparison of Electrical Ilioinguinal Nerve Stimulation With Intravesical Irrigation for Bladder Pain Syndrome","status":"COMPLETED","sponsor":"Shanghai Institute of Acupuncture, Moxibustion and Meridian","startDate":"2014-07","conditions":"Painful Bladder Syndrome","enrollment":60},{"nctId":"NCT02247557","phase":"PHASE2","title":"Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2014-09","conditions":"Interstitial Cystitis","enrollment":90},{"nctId":"NCT01816646","phase":"PHASE1","title":"Intravesical Cidofovir for Hemorrhagic Cystitis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-09","conditions":"Blood And Marrow Transplantation","enrollment":6},{"nctId":"NCT00823030","phase":"NA","title":"Effect of Intravesical Lidocaine on Urodynamic and Symptomatic Parameters of Interstitial Cystitis","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2009-01","conditions":"Interstitial Cystitis","enrollment":""},{"nctId":"NCT00583219","phase":"PHASE1, PHASE2","title":"Botulin-A Toxin Instillations and Overactive Bladder","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-03","conditions":"Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia","enrollment":25},{"nctId":"NCT01939756","phase":"PHASE1, PHASE2","title":"Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"Savino M. Di Stasi","startDate":"2012-01","conditions":"Superficial Bladder Cancer, Lower Urinary Tract Symptoms","enrollment":50},{"nctId":"NCT01458847","phase":"PHASE1","title":"Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer","status":"COMPLETED","sponsor":"BioCis Pharma Ltd","startDate":"2009-10","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":12},{"nctId":"NCT00959868","phase":"PHASE1","title":"A Study for Treatment of Superficial Bladder Cancer Using OGX-427","status":"UNKNOWN","sponsor":"Vancouver Coastal Health","startDate":"2009-07","conditions":"Bladder Cancer","enrollment":36},{"nctId":"NCT01442519","phase":"PHASE3","title":"Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"1994-01","conditions":"Bladder Cancer","enrollment":212},{"nctId":"NCT00527917","phase":"PHASE2","title":"A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2007-09","conditions":"Interstitial Cystitis","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Intravesical"},"crossReferences":{"chemblId":"CHEMBL2108251"},"_approvalHistory":[{"date":"20190419","type":"ORIG","sponsor":"HIKMA","applicationNumber":"ANDA206430"}],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Continuous Epirubicin Instillation During the Early Postoperative Period","Single-Dose Epirubicin Instillation During the Early Postoperative Period","Intravesical gemcitabin and docetaxel"],"phase":"marketed","status":"active","brandName":"Intravesical Solution","genericName":"Intravesical Solution","companyName":"Ankara Training and Research Hospital","companyId":"ankara-training-and-research-hospital","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T06:44:14.988845+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}